Skip to main content
SpringerLink
Log in

The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Bipolar disorder is marked by frequent recurrences, a course from childhood or early adulthood until death, marked increased rates of suicide, and substantial functional morbidity. Maintenance treatment is generally recommended to reduce the ravages of the illness. This article reviews the evidence that lithium, divalproex, and carbamazepine may reduce suicidal risk. It reviews the evidence for relapse prevention for lithium, valproate, and other drugs often employed in the maintenance phase treatment of bipolar disorder. Both lithium and divalproex appear beneficial in prevention of relapse, although recent studies indicate more modest effects for lithium than did early studies from the 1970s.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205–228.

    PubMed  CAS  Google Scholar 

  2. Dilsaver SC, Chen YW, Swann AC, et al.: Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994, 151:1312–1315.

    PubMed  CAS  Google Scholar 

  3. Müller-Oerlinghausen B, Muser CB, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992, 25:261–269.

    Article  PubMed  Google Scholar 

  4. Simpson SG, Jamison KR: The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999, 60 Suppl 2:53–56.

    PubMed  Google Scholar 

  5. Ahrens B, Müller-Oerlinghausen B, Grof P: Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatry 1993, 163 Suppl 21:27–29.

    Google Scholar 

  6. Isometsa ET, Henriksson MM, Aro HM, Lonnqvist JK: Suicide in bipolar disorder in Finland. Am J Psychiatry 1994, 151:1020–1024.

    PubMed  CAS  Google Scholar 

  7. Tondo L, Baldessarini RJ, Hennen J, et al.: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998, 59:405–414.

    PubMed  CAS  Google Scholar 

  8. Baldessarini RJ, Tondo L, Floris G, Rudas N: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry 1997, 154:551–553.

    PubMed  CAS  Google Scholar 

  9. Theis-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al.: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996, 29:103–107.

    Google Scholar 

  10. Greil W, Ludwig-Mayerhofer W, Erazo N, et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997, 43:151–161.

    Article  PubMed  CAS  Google Scholar 

  11. Prien RF, Caffey EM, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973, 28:337–341.

    PubMed  CAS  Google Scholar 

  12. Vestergaard P, Aagaard J: Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991, 21:33–38.

    Article  PubMed  CAS  Google Scholar 

  13. Bowden CL, Calabrese JR, McElroy SL, et al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000, 57:481–489. A large (n = 372) randomized study that provides the only blinded comparison of lithium with a mood stabilizer, and the only study to taper the mood stabilizer taken at the time of randomization, to reduce possibility of drug withdrawal-induced relapse.

    Article  PubMed  CAS  Google Scholar 

  14. Gitlin MJ, Swendsen J, Heller TL, Hammen C: Relapse and impairment in bipolar disorder. Am J Psychiatry 1995, 152:1635–1640.

    PubMed  CAS  Google Scholar 

  15. Coppen A, Noguera R, Bailey J, et al.: Prophylactic lithium in affective disorders. Lancet 1971, 2:275–279.

    Article  PubMed  CAS  Google Scholar 

  16. Cundall RL, Brooks PW, Murray LG: A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972, 2:308–311.

    Article  PubMed  CAS  Google Scholar 

  17. Baastrup PC, Poulsen JC, Schou M, et al.: Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorder. Lancet 1970, 2:326–330.

    Article  PubMed  CAS  Google Scholar 

  18. Melia PI: Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry 1970, 116:621–624.

    PubMed  CAS  Google Scholar 

  19. Stallone F, Shelley E, Mendlewicz J, Fieve RR: The use of lithium in affective disorders, III: a double-blind study of prophylaxis in bipolar disorder. Am J Psychiatry 1973, 130:1006–1010.

    PubMed  CAS  Google Scholar 

  20. Aagaard J, Vestergaard P: Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990, 18:259–266.

    Article  PubMed  CAS  Google Scholar 

  21. Tohen M, Watenaux CM, Tsuang MT: Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990, 47:1106–1111.

    PubMed  CAS  Google Scholar 

  22. Harrow M, Goldberg JF, Grossman LS, Meltzer HY: Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990, 47:665–671.

    PubMed  CAS  Google Scholar 

  23. Maj M, Pirozzi R, Magliano L, Bartoli L: Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998, 155:30–35. A systematic report of long-term outcomes with lithium treatment of bipolar disorder. It indicates good results among patients who stay with treatment for several years, but high rates of early failure, poor adherence, and dropouts.

    PubMed  CAS  Google Scholar 

  24. Schou M, Juel-Nielsen N, Stromgren E, Voldby H: The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954, 17:250–260.

    PubMed  CAS  Google Scholar 

  25. Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963, 109:56–65.

    Google Scholar 

  26. Goodwin FK, Murphy DL, Bunney WE Jr: Lithium carbonate treatment in depression and mania: a longitudinal doubleblind study. Arch Gen Psychiatry 1969, 21:486–496.

    PubMed  CAS  Google Scholar 

  27. Stokes PE, Shamoian CA, Stoll PM, Patton MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971, 1:1319–1325.

    Article  PubMed  CAS  Google Scholar 

  28. Bowden CL, Brugger AM, Swann AC, et al.: Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994, 271:918–924.

    Article  PubMed  CAS  Google Scholar 

  29. Esparon J, Kolloori J, Naylor GJ, et al.: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986, 148:723–725.

    Article  PubMed  CAS  Google Scholar 

  30. Ahlfors UG, Baastrup PC, Dencker SJ: Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981, 64:226–237.

    PubMed  CAS  Google Scholar 

  31. Okuma T, Yamashita I, Takahashi R, et al.: Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990, 23:143–150.

    Article  PubMed  CAS  Google Scholar 

  32. Lambert PA, Venaud D: Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure 1992, 5:57–65.

    Google Scholar 

  33. Calabrese JR, Delucchi GA: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990, 147:431–434.

    PubMed  CAS  Google Scholar 

  34. McElroy SL, Keck Jr, Pope Jr. HG: Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987, 7:16–24.

    PubMed  CAS  Google Scholar 

  35. Baldessarini RJ, Tohen M, Tondo L: Maintenance treatment in bipolar disorder [comment]. Arch Gen Psychiatry 2000, 57:490–492. A thoughtful editorial on the complexities of analysis of treatments for prophylaxis of bipolar disorder, with special attention to the difficulties of studying a sample fully representative of the spectrum of bipolar disorder.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78229-3900, San Antonio, TX, USA

    Charles L. Bowden MD

Authors
  1. Charles L. Bowden MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowden, C.L. The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse. Curr Psychiatry Rep 2, 490–494 (2000). https://doi.org/10.1007/s11920-000-0007-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-000-0007-5

Keywords

Search

Navigation